TriangleNCT05556616 · OUTCOME
Group 1: Percentage of Participants With MRD Negativity Status at a Threshold of 10^-5
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- At 6 months, 1 year, and 2 years after the start of treatment
What was measured
Rate of MRD negativity at a sensitivity of 10\^-5 was defined as the percentage of participants who achieved MRD negative status in the MRD-evaluable analysis set.
Analysis population: MRD data was not collected as no participant achieved the criteria for MRD-evaluable analysis set (i.e., being on study at 6 months).
Groups in this outcome
Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg
Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W, in combination with 10 mg lenalidomide capsules orally once daily continuously on Days 1 to 28, in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or to a maximum of 2 years for MRD \[-\] negative participants, whichever occurred first.
| Group | Source count |
|---|---|
| Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Rate of MRD negativity at a sensitivity of 10\^-5 was defined as the percentage of participants who achieved MRD negative status in the MRD-evaluable analysis set.
- groups
- description
- Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W, in combination with 10 mg lenalidomide capsules orally once daily continuously on Days 1 to 28, in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or to a maximum of 2 years for MRD \[-\] negative participants, whichever occurred first.
- id
- OG000
- title
- Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg
- population Description
- MRD data was not collected as no participant achieved the criteria for MRD-evaluable analysis set (i.e., being on study at 6 months).
- reporting Status
- POSTED
- time Frame
- At 6 months, 1 year, and 2 years after the start of treatment
- title
- Group 1: Percentage of Participants With MRD Negativity Status at a Threshold of 10^-5
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice